Dacomitinib is a second-generation pan-EGFR inhibitor targeting EGFR, HER2, and HER4 receptor tyrosine kinases that has been approved for the first-line therapeutics of metastatic NSCLC with EGFR mutation [49]. The gene discussed is ERBB4; the disease is non-small cell lung carcinoma.